{'52WeekChange': 0.04000008,
 'SandP52WeekChange': None,
 'address1': '2505 Meridian Parkway',
 'address2': 'Suite 100',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.47,
 'askSize': 800,
 'averageDailyVolume10Day': 495137,
 'averageVolume': 1105761,
 'averageVolume10days': 495137,
 'beta': 1.946218,
 'beta3Year': None,
 'bid': 3.46,
 'bidSize': 1000,
 'bookValue': 1.632,
 'category': None,
 'circulatingSupply': None,
 'city': 'Durham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.76,
 'dayLow': 3.41,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.027,
 'enterpriseToRevenue': 9.761,
 'enterpriseValue': 111318672,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '919 806 1146',
 'fiftyDayAverage': 3.2065713,
 'fiftyTwoWeekHigh': 3.89,
 'fiftyTwoWeekLow': 1.19,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43969302,
 'forwardEps': -0.25,
 'forwardPE': -13.8,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.17959999,
 'heldPercentInstitutions': 0.56314,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/chimerix.com',
 'longBusinessSummary': 'Chimerix, Inc., a development-stage biopharmaceutical '
                        'company, focuses on accelerating the advancement of '
                        'various medicines that impact in the lives of '
                        'patients living with cancer and other serious '
                        'diseases. Its clinical stage development programs '
                        'include dociparstat sodium (DSTAT), a potential '
                        'first-in-class glycosaminoglycan compound derived '
                        'from porcine heparin that has low anticoagulant '
                        'activity but retains the ability to inhibit '
                        'activities of key proteins implicated in the '
                        'retention and viability of acute myeloid leukemia '
                        'blasts and leukemic stem cells in the bone marrow '
                        'during chemotherapy; and brincidofovir (BCV), an '
                        'antiviral drug candidate in development as a medical '
                        'countermeasure for smallpox. The company has license '
                        'agreements with Biomedical Advanced Research and '
                        'Development Authority for the development of '
                        'brincidofovir for use in the treatment of smallpox; '
                        'Cantex Pharmaceuticals, Inc. to develop and '
                        'commercialize a glycosaminoglycan compound; SymBio '
                        'Pharmaceuticals to develop, manufacture, and '
                        'commercialize BCV for various human indications; and '
                        'University of Michigan to research, develop, '
                        'manufacture, and commercialize various products. '
                        'Chimerix, Inc. was founded in 2000 and is '
                        'headquartered in Durham, North Carolina.',
 'longName': 'Chimerix, Inc.',
 'market': 'us_market',
 'marketCap': 213659536,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_3280635',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -105303000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.66,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '919 806 1074',
 'previousClose': 3.64,
 'priceHint': 4,
 'priceToBook': 2.1139708,
 'priceToSalesTrailing12Months': 18.73549,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.76,
 'regularMarketDayLow': 3.41,
 'regularMarketOpen': 3.66,
 'regularMarketPreviousClose': 3.64,
 'regularMarketPrice': 3.66,
 'regularMarketVolume': 334930,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 61930300,
 'sharesPercentSharesOut': 0.019199999,
 'sharesShort': 1191563,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1195274,
 'shortName': 'Chimerix, Inc.',
 'shortPercentOfFloat': 0.0249,
 'shortRatio': 2.83,
 'startDate': None,
 'state': 'NC',
 'strikePrice': None,
 'symbol': 'CMRX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.809,
 'twoHundredDayAverage': 2.3107195,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '7389e162-7c43-3cdb-be64-0bc435a74d1a',
 'volume': 334930,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.chimerix.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '27713'}